4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. Nancy Miller-Rich brings 35 years of experience in the healthcare industry, with significant expertise in business development and commercial strategy. Shawn Tomasello brings over 30 years of experience in the life sciences

Click to view original post